April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
The utility of AAV2/rh10 for gene delivery to murine photoreceptors
Author Affiliations & Notes
  • Arpad Palfi
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Naomi Chadderton
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Sophia Millington-Ward
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Mary O'Reilly
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Jean Bennett
    F. M. Kirby Center for Molecular Ophthalmology, Philadelphia, PA
  • Paul Kenna
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Jane Farrar
    Genetics, Trinity College Dublin, Dublin, Ireland
  • Footnotes
    Commercial Relationships Arpad Palfi, Genable Ltd. (C); Naomi Chadderton, Genable Ltd. (C); Sophia Millington-Ward, Genable Ltd. (C); Mary O'Reilly, Genable Ltd. (C); Jean Bennett, Avalanche Technologies (C), Gensight Biologics (C), Spark Therapeutics (C); Paul Kenna, Genable Ltd. (C); Jane Farrar, Genable Ltd. (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3325. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arpad Palfi, Naomi Chadderton, Sophia Millington-Ward, Mary O'Reilly, Jean Bennett, Paul Kenna, Jane Farrar; The utility of AAV2/rh10 for gene delivery to murine photoreceptors. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3325.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Recombinant AAV, with a number of clinical trials in progress, is a favored vector for retinal gene delivery. An array of naturally occurring or engineered serotypes can be used to provide specific targeting to different cell types within the retina. However, recent studies indicate that transduction efficiencies vary significantly between species. Serotypes highly efficient in preclinical rodent studies may be less potent when evaluated in non-human primates or indeed in human patients. Therefore the isolation/creation and evaluation of new AAV serotypes is required to optimize this gene delivery technology and provide an array of serotypes, some of which may potentially be efficacious in humans. In the current study, we have investigated the applicability of AAV2/rh10 for the retina by comparing the efficacy of this serotype with AAV2/8 as a means to achieve rhodopsin replacement in a rhodopsin knock-out mouse model (Rho-/-).

Methods: A rhodopsin replacement gene driven from a rhodopsin promoter was produced in AAV2/8 and AAV2/rh10 using the triple transfection method and subsequent CsCl purification. At p3-4, Rho-/- pups were given a single subretinal injection of 4 x 10e9 vg of either rhodopsin replacement AAVs (AAV2/8-RHO or AAV2/rh10-RHO) mixed with AAV2/5-EGFP to trace injections. Performance of the treated retinas was followed up to 11 months post-delivery.

Results: Significant preservation of rhodopsin expression, the outer nuclear layer, photoreceptor segments and their ultrastructure was observed using both fluorescence and electron microscopy in the treated retinas. Electroretinography (ERG) and optokinetic tracking responses (OKR) were also significantly improved in treated mouse eyes when compared to the untreated controls suggesting that functional vision was improved. In this model system, efficacy of AAV2/8 and AAV2/rh10 for gene delivery to photoreceptors was similar in all aspects tested.

Conclusions: The results suggest that AAV2/8 and AAV2/rh10 are highly and similarly efficient in the mouse retina. Additional studies are required to test applicability of AAV2/rh10 in non-human primates and potentially in the clinic.

Keywords: 538 gene transfer/gene therapy • 648 photoreceptors • 702 retinitis  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.